

United States Patent [19]
Sharland

[11] **4,036,968**
[45] **July 19, 1977**

[54] **PHARMACEUTICAL TABLET**

[75] Inventor: **David Cedric Sharland**, Worthing,
England

[73] Assignee: **Beecham Group Limited**, England

[21] Appl. No.: **644,424**

[22] Filed: **Dec. 29, 1975**

Related U.S. Application Data

[62] Division of Ser. No. 485,163, July 2, 1974, Pat. No.
3,996,365.

[30] **Foreign Application Priority Data**

July 12, 1973 United Kingdom 33214/73

[51] Int. Cl.² **A61K 31/43**

[52] U.S. Cl. **424/271**

[58] Field of Search 424/271, 166

[56] **References Cited**

PUBLICATIONS

The Merck Index, 8th Ed., Merck & Co., Inc., Rahway,
N. J., 1968, pp. 271, 354 and 355.
Chemical Abstracts 58:1679f (1963).

Primary Examiner—Jerome D. Goldberg

[57] **ABSTRACT**

A pharmaceutical tablet which comprises at least 20 per
cent by weight of one or more β -lactam antibiotics and
from 0.1 to 4 parts by weight of urea per part of said
 β -lactam antibiotic.

6 Claims, No Drawings

to maximize the advantages of this invention, film coatings, when present, should not consist of substantial amounts of acid insoluble materials.

The tablets of the invention may be prepared by blending together the ingredients and compressing in conventional manner. Film coatings may be applied after the formation of the tablet coat.

The tablets of the invention may frequently be prepared by direct compression (that is simply blend the materials and compress directly into tablets) although if desired a multiple compression technique may be employed (for example the materials apart from some lubricant may be blended together, compressed into slugs, reduced to granules, blended with further lubricant and compressed into granules).

An excipient almost always favorable in the tablets of this invention is a lubricant such as stearic acid or, more preferably, magnesium stearate.

It has been found that superior tablets result if the urea used in the preparation has been pretreated with methylene dichloride in order to modify its crystal form. Other solvents which may be used to partially modify the urea are mixtures of methylene dichloride and isopropyl alcohol or wetted methylene dichloride. Such partially modified urea does not generally produce such acceptable tablets.

An important aspect of this invention lies in the use of such modified urea in the preparation of pharmaceutical tablets.

It is highly preferable that this modified urea is used in the tablets of this invention as it generally results in the production of tablets with improved properties such as increased tablet strength.

The urea may be modified as follows: to 700g of urea was added sufficient methylene dichloride to wet all the crystals surfaces (about 500 ml) and the wetted crystals were then mixed in a planetary mixer for 5 minutes. The material was transferred to a forced air oven and dried for 2 hours at 70° C.

A suitable coat comprises an approximately 5:1:1 mixture of hydroxypropylmethyl cellulose, propylene glycol and titanium dioxide or color. Usually such materials are made to form a suspension in an organic solvent and sprayed onto the tablets which are then dried in a current of air.

In the following Examples dissolution rates were determined by stirring at 30 r.p.m. in a buffered solution at 37° C.

The following Examples illustrate the invention:

EXAMPLE 1

The sodium salt of β -phenoxycarbonylbenzylpenicillin was formulated into tablets having the following composition:

Active compound	528 mg
Urea	712 mg
Magnesium Stearate	20 mg

The penicillin, urea and half the magnesium stearate were blended together, compressed into slugs, broken up into granules, blended with the rest of the magnesium stearate and recompressed into tablets.

EXAMPLES 2-4

Tablets were produced as in Example 1 in which the α -phenoxycarbonyl benzylpenicillin was replaced respectively by the sodium salts of the equivalent α -[2-iso-

propylphenoxycarbonyl] 5-indanyloxycarbonyl and α -[4-carbomethonylphenoxycarbonyl] compounds.

EXAMPLES 5-9

Tablets were produced as in Example 1 in which the quantities of ingredients (in mg) were as follows:

Active Compound	500	350	490	600	500
Urea	750	700	490	380	600
Magnesium Stearate	20	20	20	20	20
Heavy Magnesium Carbonate	0	0	0	0	200

EXAMPLE 10

Tablets were prepared as in Example 1 in which the carbenicillin ester was replaced by an equal amount of (a) sodium benzylpenicillin or (b) sodium phenoxymethylpenicillin.

EXAMPLE 11

The sodium salt of α -phenoxycarbonyl benzyl penicillin was formulated into tablets having the composition:

Active compound	518 mg
Urea	712 mg
Magnesium Stearate	20 mg
	1250 mg

The tablets were produced by the slugging route and possessed the ability to release 90% of the drug within 13 minutes when tested at pH 2.5. Applying a film coat increased the t_{90} to 27 minutes and when these tablets were tested under in-vivo conditions a urinary recovery of 50% was obtained within 6 hours. This compares to a maximum recovery of 56% obtained from a syrup. [t_{90} is the time required for 90% of the medicament to be released]

EXAMPLES 12-15

Tablets were produced as in Example 11 in which the quantities of ingredients (in mgs) were as follows:

Active compound	518	518	518	258
Urea	171.6	368.4	585.4	185.2
Magnesium Sulphate	10.4	13.6	16.6	6.8
	700	900	1200	450
in vitro t_{90} uncoated-mins	17	15	12.5	—
in vitro t_{90} film coated-mins	27	27	27	28
in vivo urinary recovery 0-6 hours	44%	47%	—	—

EXAMPLE 16

The phthalide ester of ampicillin was formulated via direct compression into tablets having the composition:

Active compound	399.4 mg
Magnesium Stearate	10.6 mg
Sodium lauryl sulphate	15.0 mg
Urea	400.0 mg
	825.0 mg

At a pH of 1.5 these tablets gave an in-vitro dissolution of 90% within 12 minutes.

5

EXAMPLE 17

The sodium salt of cloxacillin was formulated via direct compression into tablets having the composition:

Active compound	573 mg
Urea	67 mg
Magnesium Stearate	10 mg
	650 mg

At a pH of 4.0 the tablets gave in-vitro drug dissolutions of 90% within 16 minutes.

EXAMPLE 18

The sodium salt of flucloxacillin was formulated via the direct compression route into tablets having the composition:

Active material	587 mg
Urea	153 mg
Magnesium Stearate	10 mg
	750 mg

At a pH of 4.0 the tablets gave in-vitro results of 9 minutes for 90% dissolution.

EXAMPLE 19

Two penicillins incorporated into a tablet have been produced to the formula:

Amoxycillin Trihydrate	603 mg
Sodium flucloxacillin	587 mg
Urea	400 mg
Magnesium Stearate	10 mg
	1600 mg

Tablets prepared by the direct compression route yielded tablets giving an in-vitro total penicillin dissolution of 12.5 minutes for 90% at a pH of 4.0.

EXAMPLE 20

The use of a supporting buffer can be demonstrated with the phenyl ester of carbenicillin.

Active Compound	512 mg
Magnesium Stearate	11 mg
Urea	271 mg
Heavy Magnesium Carbonate	120 mg
Primogel	48 mg
Sodium lauryl sulphate	8 mg
	970 mg

The tablets were produced by slugging together a blend of the penicillin urea and part of the magnesium stearate, reducing into granules, blending with the re-

6

maining materials and compressing into tablets. These tablets exhibited an in-vitro dissolution of 90% within 28 minutes at pH of 2.5.

EXAMPLE 21

Cephaloglycin was incorporated into tablets having the formulation:

Cephaloglycin dihydrate	275.0 mg
Magnesium Stearate	6.5 mg
Urea	368.5 mg
	650.4 mg

Tablets prepared by direct compression produced times of 5 minutes for 90% dissolution at a pH of 1.5.


EXAMPLE 22

The sodium salt of the α -phenyl ester of ticarcillin was formed by the slugging route into tablets having the composition:

Active compound	500	500	300
Urea	170	300	190
Magnesium stearate	10	15	10

What we claim is:

1. A pharmaceutical tablet which comprises 10% to 70% urea and an antibacterially effective amount of at least 20% of a penicillin of the formula



wherein R_3 is a hydrogen, chlorine or fluorine atom, or a pharmaceutically acceptable salt thereof.

2. A tablet according to claim 1 wherein the penicillin is cloxacillin or flucloxacillin.

3. A tablet according to claim 1, wherein the penicillin is the sodium or potassium salt of cloxacillin or flucloxacillin.

4. A tablet according to claim 1 which comprises 20% to 60% urea.

5. A tablet according to claim 1 which comprises at least 50% urea.

6. A tablet according to claim 1 wherein each tablet contains 150 to 600 mg of urea and 250 to 750 mg of the penicillin or sodium or potassium salt thereof.

* * * * *